Stock Track | Harmony Biosciences Soars 5.17% on Strong Q1 Results and Reaffirmed Guidance

Stock Track

May 06, 2025

Harmony Biosciences Holdings, Inc. (HRMY) stock surged 5.17% in pre-market trading on Tuesday following the release of its better-than-expected first-quarter financial results. The rare neurological disease-focused pharmaceutical company reported adjusted earnings of $1.03 per diluted share, significantly surpassing the FactSet analyst consensus estimate of $0.83 per share.

The company's strong performance was further underscored by its impressive revenue growth. Harmony Biosciences posted Q1 product revenue of $184.73 million, exceeding analysts' expectations of $182.9 million. This represents a substantial increase from $154.6 million in the same quarter last year. Additionally, the company reported a robust gross profit of $152.739 million and an operating income of $56.245 million for the quarter.

Investors were also encouraged by Harmony Biosciences' reaffirmation of its full-year 2025 revenue guidance. The company maintains its outlook of $820 million to $860 million in product revenue, aligning with the current FactSet analyst consensus of $840.4 million. This positive outlook, combined with the strong Q1 results, has bolstered investor confidence in Harmony Biosciences' growth trajectory, driving the stock's pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1167786464"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167786464\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167786464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-06 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167786464","market":"nz","top_or_hot":-1,"title":"Stock Track | Harmony Biosciences Soars 5.17% on Strong Q1 Results and Reaffirmed Guidance","media":"Stock Track","content":"<p>Harmony Biosciences Holdings, Inc. (HRMY) stock surged 5.17% in pre-market trading on Tuesday following the release of its better-than-expected first-quarter financial results. The rare neurological disease-focused pharmaceutical company reported adjusted earnings of $1.03 per diluted share, significantly surpassing the FactSet analyst consensus estimate of $0.83 per share.</p>\n\n<p>The company's strong performance was further underscored by its impressive revenue growth. Harmony Biosciences posted Q1 product revenue of $184.73 million, exceeding analysts' expectations of $182.9 million. This represents a substantial increase from $154.6 million in the same quarter last year. Additionally, the company reported a robust gross profit of $152.739 million and an operating income of $56.245 million for the quarter.</p>\n\n<p>Investors were also encouraged by Harmony Biosciences' reaffirmation of its full-year 2025 revenue guidance. The company maintains its outlook of $820 million to $860 million in product revenue, aligning with the current FactSet analyst consensus of $840.4 million. This positive outlook, combined with the strong Q1 results, has bolstered investor confidence in Harmony Biosciences' growth trajectory, driving the stock's pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harmony Biosciences Soars 5.17% on Strong Q1 Results and Reaffirmed Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harmony Biosciences Soars 5.17% on Strong Q1 Results and Reaffirmed Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-06 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harmony Biosciences Holdings, Inc. (HRMY) stock surged 5.17% in pre-market trading on Tuesday following the release of its better-than-expected first-quarter financial results. The rare neurological disease-focused pharmaceutical company reported adjusted earnings of $1.03 per diluted share, significantly surpassing the FactSet analyst consensus estimate of $0.83 per share.</p>\n\n<p>The company's strong performance was further underscored by its impressive revenue growth. Harmony Biosciences posted Q1 product revenue of $184.73 million, exceeding analysts' expectations of $182.9 million. This represents a substantial increase from $154.6 million in the same quarter last year. Additionally, the company reported a robust gross profit of $152.739 million and an operating income of $56.245 million for the quarter.</p>\n\n<p>Investors were also encouraged by Harmony Biosciences' reaffirmation of its full-year 2025 revenue guidance. The company maintains its outlook of $820 million to $860 million in product revenue, aligning with the current FactSet analyst consensus of $840.4 million. This positive outlook, combined with the strong Q1 results, has bolstered investor confidence in Harmony Biosciences' growth trajectory, driving the stock's pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRMY","symbol_name":"Harmony Biosciences Holdings, Inc.","start_time":0,"source_url":"","article_id":"1167786464","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167786464","pubTimestamp":1746538560,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harmony Biosciences Holdings, Inc.  stock surged 5.17% in pre-market trading on Tuesday following the release of its better-than-expected first-quarter financial results. The rare neurological disease-focused pharmaceutical company reported adjusted earnings of $1.03 per diluted share, significantly surpassing the FactSet analyst consensus estimate of $0.83 per share.The company's strong performance was further underscored by its impressive revenue growth. Harmony Biosciences posted Q1 product r","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc."},"translate_title":"Harmony Biosciences因强劲的第一季度业绩和重申的指引而飙升5.17%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":1},"content_text":"Harmony Biosciences Holdings, Inc. (HRMY) stock surged 5.17% in pre-market trading on Tuesday following the release of its better-than-expected first-quarter financial results. The rare neurological disease-focused pharmaceutical company reported adjusted earnings of $1.03 per diluted share, significantly surpassing the FactSet analyst consensus estimate of $0.83 per share.\nThe company's strong performance was further underscored by its impressive revenue growth. Harmony Biosciences posted Q1 product revenue of $184.73 million, exceeding analysts' expectations of $182.9 million. This represents a substantial increase from $154.6 million in the same quarter last year. Additionally, the company reported a robust gross profit of $152.739 million and an operating income of $56.245 million for the quarter.\nInvestors were also encouraged by Harmony Biosciences' reaffirmation of its full-year 2025 revenue guidance. The company maintains its outlook of $820 million to $860 million in product revenue, aligning with the current FactSet analyst consensus of $840.4 million. This positive outlook, combined with the strong Q1 results, has bolstered investor confidence in Harmony Biosciences' growth trajectory, driving the stock's pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}